Intranasal RSV Vaccine Clinical Trial for Infants, Toddlers and Preschoolers

The human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in infants and an important cause of hospitalization in children < 5 years. [source: ncbi.nlm.nih.gov]. We are currently seeking children in Boise, Cleveland, Austin and Hastings to participate in our latest intranasal RSV vaccine clinical study. Contact us today to see if your child qualifies.

Eligibility Requirements*:

• Infants and children from ages 6 months to 5 years
• May or may not have had RSV in the past
• In overall good health

*Note additional criteria applies

Qualified Enrolled Participants May Receive

• Study-related care from Velocity Clinical Research
• Investigational intranasal vaccine
• Compensation for time or travel